11 Amendments of Stanislav POLČÁK related to 2019/2816(RSP)
Amendment 6 #
Citation 1 a (new)
– having regard to Article 11 of the Treaty on the Functioning of the European Union,
Amendment 7 #
Citation 1 b (new)
– having regard to Article 191 of the Treaty on the Functioning of the European Union,
Amendment 8 #
Citation 1 c (new)
– having regard to the 7th Environment Action Programme to 2020 ‘Living well, within the limits of our planet’, as adopted by Decision 1386/2013/EU of the European Parliament and of the Council of 20 November 2013,
Amendment 32 #
Citation 24 a (new)
– having regard to the Commission document entitled 'Towards a sustainable Europe by 2030',
Amendment 38 #
Recital B
B. whereas the wide use of pharmaceuticalactive substances in human and veterinary medicines, including antimicrobial agents, has increased their concentrations in many environmental reservoirs such as soils, sediments and waterbodies in the past 20 years; whereas the trend towards increasing consumption of pharmaceuticals for human use is likely to continue as the population gradually ages and grows; whereas the largest source of pharmaceuticals entering the environment is their use and disposal;
Amendment 50 #
Recital D a (new)
D a. whereas the chemical and/or metabolic stability of certain pharmaceuticals means that up to 90 % of their active substances are released into the environment in their original form after use;
Amendment 56 #
Recital F a (new)
F a. whereas, in its proposed communication, the Commission itself acknowledges the knowledge gaps in terms of concentrations of certain pharmaceuticals in the environment and the resulting levels of risk;
Amendment 87 #
Paragraph 5
5. Considers that a holistic approach is needed to tackle pharmaceutical pollution, taking into account the entire life cycle of drugs; stresses that regulatory actions have to be taken in line with, in order to ensure the effectiveness of the regulatory actions being adopted, it is vital that they are adopted in line with the prevention principle and the precautionary principle; highlights, furthermore, that the polluter pays principle should apply, primarily covering the manufacturing process, but also incentivising better prescription practices and consumer behaviour;
Amendment 118 #
Paragraph 10
10. Asks, with regard to the effectiveness of the measures being adopted, for a special focus to be put on emission hot spots, such as hospitals and pharmaceutical production plants;
Amendment 185 #
Paragraph 22
22. Considers that a clear road map for completing environmental risk assessments on pharmaceuticals placed on the EU market is needed, where thosesuch assessments are not available;
Amendment 214 #
Paragraph 29
29. Considers that pharmaceutical production plants should pre-treat their wastewater in accordance with the principle of preventing environmental threats, especially at source;